Beyond Effectiveness: Evaluating the Public Health Impact of the WISEWOMAN Program
Rosanne P. Farris, PhD,
Julie C. Will, PhD,
Olga Khavjou, MA and
Eric A. Finkelstein, PhD
Rosanne P. Farris and Julie C. Will are with the Centers for Disease Control and Prevention, Division for Heart Disease and Stroke Prevention, Atlanta, Ga. Olga Khavjou and Eric A. Finkelstein are with RTI International, Health, Social, and Economics Research, Research Triangle Park, NC.
FIGURE 1——Flowchart of the use of the RE-AIM framework for the evaluation of a WISEWOMAN program in general and as a component of NBCCEDP
Note. RE-AIM = reach, efficacy and effectiveness, adoption, implementation, and maintenance; WISEWOMAN = Well-Integrated Screening and Evaluation for Women Across the Nation; NBCCEDP = National Breast and Cervical Cancer Early Detection Program.
aData already collected but not available at the site level.
bPlanned future data collection.
cAppropriate measure for research but not for public health programs.
dAppropriate measure for public health programs but ability to collect additional data is limited.
FIGURE 2——North Carolina WISEWOMAN RE-AIM evaluation framework dimensions: 2 sites with high performance (sites D and E) and 2 sites with low performance (sites K and L).
Note. RE-AIM = reach, efficacy or effectiveness, adoption, implementation, and maintenance; WISEWOMAN = Well-Integrated Screening and Evaluation for Women Across the Nation. Scores fell into 1 of the following tertiles: tertile 1 = 0–33.3; tertile 2 = 33.3–66.6; tertile 3 = 66.6–100.
